(fezolinetant), a treatment for moderate to severe vasomotor symptoms (vms) related to menopause, will be presented at the international menopause society world congress in melbourne from october 19-22, 2024. the pres clinical trial menopause socci 1 0 0 0 fda approves inavolisib with soc in...
The scoop: Vasomotor symptoms, or hot flashes and night sweats, make up some of the most dreaded and common characteristics of menopause. Veozah represents a new option as the first nonhormonal neurokinin 3 (NK3) receptor antagonist approved for the condition. The nonhormonal asp...